Taltz in Combination With Enstilar for Psoriasis
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Psoriasis
- Type
- Interventional
- Phase
- Phase 4
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentIntervention Model Description: open-labelMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
A single center study of 25 subjects to assess the addition of Enstilar Foam in patients receiving Taltz for ? 24 weeks with BSA between 3% and 8%.
A single center study of 25 subjects to assess the addition of Enstilar Foam in patients receiving Taltz for ? 24 weeks with BSA between 3% and 8%.
Tracking Information
- NCT #
- NCT04372277
- Collaborators
- Eli Lilly and Company
- Investigators
- Not Provided
Get Well Soon